A First-in-Human Open-Label Phase 1/2a Study to Evaluate Safety, Tolerability and Efficacy of a Single Intra-Articular Injection of Allogeneic Mesenchymal Stem Cells Selected for Integrin α10β1 (XSTEM-OA) in Adult Patients with Symptomatic Knee Osteoarthritis.
Year: 2023
Type: Musculoskeletal
Phase: First-in-Human, I, IIa
Indication: Knee Osteoarthritis
A Multiple Arm, Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase 2 Study of Intra-Articular Administration of an Allogeneic Human Placental Tissue Particulate (PTP-001) for the Treatment of Knee Osteoarthritis.
Year: 2022
Type: Musculoskeletal
Phase: II
Indication: Knee Osteoarthritis
A 5-year, Randomized, Double-blind, Placebo-controlled, Multi-center Study Assessing the Efficacy, Safety, and Tolerability of Intra-articular Regimens of LNA043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis (ONWARDS).
Year: 2021
Type: Musculoskeletal
Phase: IIb
Indication: Knee Osteoarthritis
Upadacitinib treatment patterns, achievement of treatment targets and maintenance of response in moderate to severe Rheumatoid Arthritis patients in real-world practice (UPHOLD).
Year: 2020
Type: Musculoskeletal
Phase: Post-Market
Indication: Rheumatoid Arthritis
Real World Effectiveness of Upadacitinib on Early and Sustained Pain Control in Radiographic Axial Spondyloarthritis (UPSTAND).
Year: 2021
Type: Musculoskeletal
Phase: Post-Market
Indication: Spondyloarthritis
A Randomized, Active-Controlled, Parallel Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis.
Year: 2021
Type: Musculoskeletal
Phase: IIIb, IV
Indication: Rheumatoid Arthritis
A Multicenter Open-Label Study Of Etanercept Withdrawal And Retreatment In Subjects With Non-Radiographic Axial Spondyloarthritis Who Achieved Adequate 24 Week Response.
Year: 2016
Type: Musculoskeletal
Phase: IV
Indication: Spondyloarthritis
A Phase 3b/4 Randomized Double-Blind Placebo Controlled Study Of Methotrexate (Mtx) Withdrawal In Subjects With Rheumatoid Arthritis (Ra) Treated With Tofacitinib 11mg Modified Release (Mr) Formulation.
Year: 2017
Type: Musculoskeletal
Phase: IIIb, IV
Indication: Rheumatoid Arthritis
A 12 Week Randomized, Double-Blind, Double Dummy, Parallel Group, Active And Placebo-Controlled, Multicenter Study To Assess The Efficacy And Safety Profile Of Pf-06650833 In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To Methotrexate.
Year: 2017
Type: Musculoskeletal
Phase: II
Indication: Rheumatoid Arthritis
A Phase 3, Randomized, Double blind, Placebo controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are Intolerant to Biologic DMARD Therapy.
